Sun Life Q2 2026: Underlying Net Income Soars, ROE Hits 19.1%

What happened

Sun Life delivered double-digit underlying net income growth in Q2 2026, driven by strength across Canada, Asia, and the U.S., with underlying ROE reaching 19.1%—above its 18% medium-term target. The result validates the bull case in our earlier DeepValue report, which highlighted underappreciated growth in Asia and asset management as key drivers. The U.S. segment, previously a drag from group morbidity, showed strong growth, suggesting successful repricing and normalization. Combined with the continued expansion of SLC Management and resilient capital ratios, the quarter reinforces Sun Life’s high-quality, capital-light earnings profile. While the press release likely omits lingering risks, the numbers strongly support the investment thesis.

Implication

For investors, the Q2 2026 print materially reduces downside risks from U.S. morbidity and MFS outflows, confirming the thesis that Asia and asset management can power mid-single-digit EPS growth and high-teen ROE. The 19.1% ROE suggests management may even exceed targets, making the $70 trim level seem conservative if growth persists. The pullback in mid-2025 toward the high-$50s now looks like a clear buying opportunity, and the current price likely reflects growing optimism. We would raise our conviction and consider adjusting the attractive entry zone upward. However, the stock’s premium valuation likely remains, so disciplined position sizing is still advised.

Thesis delta

The Q2 2026 results directly address the key risk of U.S. group morbidity by reporting strong U.S. growth, while overall ROE surged to 19.1%, well above the 18% target. This materially strengthens the bull case, shifting the thesis from ‘potential buy’ to a more confident buy with a higher probability of achieving the $75 bull-case scenario. Consequently, we would raise conviction and may lift our trim threshold, but monitor whether the strong quarter reflects sustainable trends rather than one-off gains.